Alpine Immune Sciences To Present New Translational Data On Povetacicept And Acazicolcept In Systemic Lupus Erythematosus At American College Of Rheumatology Convergence 2023

Alpine Immune Sciences Inc Delist

Alpine Immune Sciences Inc

ALPN

64.97

Delist

Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, announced the Company will present new translational data for povetacicept and acazicolcept in systemic lupus erythematosus at American College of Rheumatology Convergence 2023, November 10-15, 2023.

American College of Rheumatology Convergence 2023

Povetacicept

Date/Time: Tuesday, November 14, 2023, 9:00 am – 11:00 am PT

Poster Title: Upregulation of Both APRIL and BAFF in Systemic Lupus Erythematosus Suggests Non-Redundant Roles, Further Revealed by Dual Inhibition with Povetacicept (ALPN-303)

Abstract ID: 1553950

Session Name: SLE – Treatment Poster III

Location: Exhibit Hall, San Diego Convention Center, San Diego, CA

Presenter: Tiffany Blair, Ph.D., Alpine Immune Sciences

Acazicolcept

Date/Time: Sunday, November 12, 2023, 9:00 am – 11:00 am PT

Poster Title: Dual Blockade of ICOS and CD28 with Acazicolcept (ALPN-101) Reveals Non-Redundant Roles of T Cell Co-Stimulation Pathways in Systemic Lupus Erythematosus

Abstract ID: 1553700

Session Name: SLE – Treatment Poster I

Location: Exhibit Hall, San Diego Convention Center, San Diego, CA

Presenter: Elizabeth Repash, M.S., Alpine Immune Sciences

About Povetacicept (ALPN-303)

Povetacicept (ALPN-303) is a dual antagonist of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, which play key roles in pathogenesis of multiple autoimmune diseases via their roles in the activation, differentiation and/or survival of B cells, particularly antibody-secreting cells, as well as T cells and innate immune cells. Based upon an engineered TACI (transmembrane activator and CAML interactor) domain, povetacicept has exhibited greater potency in preclinical studies versus wild-type TACI-based comparators, as well as other inhibitors of BAFF and/or APRIL alone and B cell depletion. Povetacicept is in development for multiple autoimmune diseases, including systemic lupus erythematosus, IgA nephropathy and other autoimmune kidney diseases, and autoimmune cytopenias.

About Acazicolcept (ALPN-101)

Acazicolcept (ALPN-101) is a first-in-class, dual inhibitor of the CD28 and ICOS T-cell costimulatory pathways being developed for treatment of systemic lupus erythematosus (SLE). By simultaneously blocking two key costimulatory pathways, acazicolcept has the potential to improve outcomes in patients suffering from severe autoimmune/inflammatory diseases. Preclinical studies have demonstrated efficacy in models of SLE, Sjögren's syndrome, arthritis, inflammatory bowel disease, multiple sclerosis, type 1 diabetes, uveitis, and graft versus host disease.

Every question you ask will be answered
Scan the QR code to contact us
whatsapp
Also you can contact us via